Relative potency of the atropine-like effects of a new parasympatholytic drug, scopolamine-N-(cyclopropyl methyl) bromide and those of hyoscine-N-butyl bromide.
A double-blind crossover trial with a 4-point bioassay was carried out in 8 convalescent in-patients  to study the relative potency of scopolamine-N-(cyclopropyl methyl) bromide (DA 3177), a new parasympatholytic drug, administered at doses of 2.5 mg and 5 mg i.v., and hyoscine-N-butyl bromide, administered at doses of 10 mg and 20 mg i.v., in producing atropine-like effects. The results showed that the effects on heart rate and near point of accommodation were slightly less with DA 3177, while its effects on salivary secretion were a little greater than those of hyoscine-N-butyl bromide. It is suggested that study of the pharmacodynamic effects of parasympatholytic drugs is a relatively simple way of predicting which doses should be effective spasmolytically.
D000065:Accommodation, Ocular / Q000187:drug effects; D000328:Adult; D002086:Butylscopolammonium Bromide / Q000008:administration & dosage / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D012469:Salivary Glands / Q000187:drug effects / Q000378:metabolism; D012602:Scopolamine Derivatives / Q000008:administration & dosage / Q000494:pharmacology*
D012602:Scopolamine Derivatives; D002086:Butylscopolammonium Bromide